Core Insights - Real Estate Investment Trusts (REITs) have experienced an average surge of over 30% in the past year, leading to a perception among investors that it may be too late to invest in them [1] Group 1 - The average increase in REITs over the past year is over 30% [1] - There is a growing sentiment among investors that the opportunity to invest in REITs has passed [1] Group 2 - High Yield Landlord offers a 2-week free trial for full access to their portfolio and current top picks [1] - The community has over 2,000 members and boasts a 4.9 out of 5 rating from more than 500 reviews [1]

You won't be charged a penny during the free trial, so you have nothing to lose and everything to gain.If you want full access to our Portfolio and all our current Top Picks, feel free to join us at High Yield Landlord for a 2-week free trial.But the reality is that from the perspective of an investor, this likely isn't such a big deal as everyone makes it seem to be.He is the leader of the investing group High Yield Landlord , where he shares his real-money REIT portfolio and transactions in real-time. Fea ...

Group 1 - Several blue-chip dividend growers have recently dipped significantly despite a broader market rally [1] - The service offers a two-week free trial, allowing potential members to access high-yield portfolios that have outperformed the market [1][2] - The service has received a perfect rating of 5/5 from 180 reviews, indicating strong member satisfaction [1] Group 2 - The service emphasizes a balanced, evidence-based approach to stock analysis, which is beneficial for income investors seeking reliable yields [3] - The focus is on identifying relatively unknown investment opportunities rather than just promoting well-known high-yield stocks [4] - Members express high satisfaction with the research quality and investment suggestions, particularly as they approach retirement [5]

Core Insights - IDEAYA Biosciences has nominated IDE034 as a development candidate, which is a potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) [1][2] - The company has exercised an option for an exclusive worldwide license for IDE034 from Biocytogen, indicating a strategic partnership [1][5] - IDEAYA aims to file for Investigational New Drug (IND) status with the FDA in 2025, targeting first-in-human clinical evaluations [1][4] Company Developments - IDE034 has shown robust tumor regressions in multiple preclinical models, highlighting its potential as a monotherapy and in combination with IDEAYA's PARG inhibitor IDE161 [2] - The co-expression rates of B7H3/PTK7 in lung, colorectal, and head and neck cancers are approximately 30%, 46%, and 27%, respectively, indicating a significant market opportunity [2][6] - IDEAYA's strategic objectives include the potential for monotherapy activity and application in priority solid tumor types [2] Financial Aspects - The total financial commitment for the license agreement with Biocytogen amounts to $406.5 million, which includes up to $100 million in development and regulatory milestone payments [5] - IDEAYA will pay upfront and option exercise fees, along with additional milestone payments and royalties on net sales [5] Partnership Insights - Biocytogen's proprietary RenLite® platform is validated through this partnership, which aims to impact patients with solid tumors [3] - The collaboration is expected to advance the IDE034 program towards clinical trials, enhancing both companies' capabilities in oncology [3]

Generally speaking, I am bullish on REITs ( VNQ ). You probably know this if you have followed my work here on Seeking Alpha. I invest over half of my portfolio in REITs because I think that they are today offeringIf you want full access to our Portfolio and all our current Top Picks, feel free to join us at High Yield Landlord for a 2-week free trial.We are the largest and best-rated real estate investor community on Seeking Alpha with 2,000+ members on board and a 4.9 /5 rating from 500+ reviews:You won't ...

Core Insights - Dividend-paying stocks consistently outperform non-dividend-paying stocks, providing a reliable income stream and long-term wealth generation [1][2][3] Dividend Investing Overview - Dividend stocks have shown impressive performance, with a 50-year study indicating an annual return of 9.17% for dividend payers compared to 4.27% for non-payers [3] - These stocks are less volatile, appealing to investors seeking stability alongside growth [3] High-Yield Dividend Stocks Agree Realty - Offers a 4.1% dividend yield and manages retail properties, with 99.6% of its properties leased and a weighted average remaining lease term of 7.9 years [5][6] - Major tenants include Walmart and Dollar General, with no single tenant exceeding 6.1% of annualized base rent [7] - Despite rising interest rates, Agree Realty invested $524.9 million in 2024 across 144 properties, ensuring steady rental income [8] - The company maintains a strong balance sheet with a low leverage ratio and a payout ratio of 73% of adjusted funds from operations [9] Realty Income - Provides a 5.5% dividend yield and has a 53-year history in commercial real estate, with a diverse portfolio of over 15,450 properties [10][11] - Utilizes triple-net leases, allowing for steady cash flow and lower rents, with 91% of its portfolio in retail properties [12][13] - The largest tenant, Dollar General, accounts for only 3.4% of annual rent, reducing reliance on any single client [14] Stag Industrial - Features a 3.9% dividend yield and focuses on U.S. industrial properties, owning 573 properties primarily in warehouses and distribution centers [15][17] - Major tenants include Amazon, contributing 3% to annual base rental revenue, with a diverse tenant base [16] - Positioned to benefit from a projected 8% compound annual growth rate in the global warehousing and distribution market through 2030 [18]

Group 1 - The market sentiment for REITs has significantly declined in recent years due to the pandemic and rising interest rates, leading to historically low valuations [1] - Many REITs are currently considered undervalued, presenting potential investment opportunities [1] Group 2 - The real estate investor community on Seeking Alpha is the largest and best-rated, with over 2,000 members and a rating of 4.9 out of 5 from more than 500 reviews [2] - The community offers a free trial for new members, allowing them to access portfolio insights without any initial cost [2]

Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphomaPoster presentation of first interim futility analysis of ongoing investigator-initiated Phase 2 clinical trial studying ZYNLONTA as treatment for r/r marginal zone lymphomaLAUSANNE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug ...

Core Insights - Defence Therapeutics Inc. has received a 30-day extension approval from the Canadian Securities Exchange for its non-brokered private placement of units priced at $0.50 per unit [3] - The first tranche of the offering closed on October 30, 2024, raising gross proceeds of $775,000 from the sale of 1,550,000 units [3] - The upcoming tranche of financing will support the development of Defence's preclinical radiopharmaceuticals and antibody-drug conjugates (ADCs) programs, utilizing its proprietary Accum® technology platform [4] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing radio-immuno-conjugates and ADC products, along with novel immune-oncology vaccines [5] - The core technology of Defence is the ACCUM® platform, which allows for precision delivery of therapeutic agents to target cells, enhancing efficacy against cancer and infectious diseases [5]

Group 1 - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) and is advancing proprietary ADC technology for treating hematologic malignancies and solid tumors [2][3] - The company will participate in two investor conferences in November 2024, with CEO Ameet Mallik presenting at both events [1] - ZYNLONTA, ADC Therapeutics' CD19-directed ADC, has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma [3] Group 2 - The investor conferences are scheduled for November 11 and November 19, 2024, with live webcasts available on the company's website [1] - ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development, indicating a robust pipeline [3] - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey [4]